arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Acumen Pharmaceuticals, Inc.

ABOS Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$1.99
▼ -2.2% Today
as of Oct 23, 15:00 ET
Last 30 days -28.85% Sep 14 → Oct 23
$1.57 $1.93 $2.28 $2.63 $2.99 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.03
High
$2.14
Low
$2.01
Volume
$569,418
Avg Vol
$499,369
Mkt Cap
$150M
P/E (TTM)
—
Beta
—
52w High
$3.60
52w Low
$1.50
Div Yield
—
Shares Out
$72M

Recent Press Releases & News last 60 days · 4 items

Oct 22 · 11:30 PR GlobeNewswire
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Oct 19 · 20:00 PR GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
Sep 10 · 20:00 PR GlobeNewswire
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
▸ Show all 4 press releases & news Free account →

ABOS earnings at a glance

The options market is pricing a move of about ±49.0% after the report, a range of roughly $1.01 to $2.97 from today's $1.99. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±1.8% on average; after the most recent report on May 12, 2026 it moved -3.5%. That means options currently expect more movement than ABOS has typically delivered. ABOS beat the consensus EPS estimate in 2 of its last 3 reported quarters. Implied volatility is currently 354%. The share price of $1.99 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.50
$3.60
23% of range
Avg surprise (last 3)
+6.2%
Avg reaction (last 2)
-1.8%
0% positive
Latest IV / EM
354%
EM ±49.0% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.68$-0.57$-0.46$-0.35$-0.24 Actual $-0.28Actual $-0.28Actual $-0.24Actual $-0.25Actual $-0.34Actual $-0.50Actual $-0.48Est $-0.56Actual $-0.68Est $-0.54Actual $-0.44Est $-0.63Actual $-0.33Actual $-0.45 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-41M$-36M$-31M$-27M$-22M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.45 — — — — financials
Tue May 12, 2026Mar/2026 $-0.33 — — +31.2% -3.5% earnings
Wed Nov 12, 2025Sep/2025 $-0.44 $-0.63 +30.2% — — earnings
Tue Aug 12, 2025Jun/2025 $-0.68 $-0.54 -25.9% — — earnings
Tue May 13, 2025Mar/2025 $-0.48 $-0.56 +14.3% — 0.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.50 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.34 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.25 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.24 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.28 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.28 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-33M$-21M—$-27M$-42M$-30M—$-32M
Net income$-33M$-21M—$-26M$-41M$-29M—$-30M
EPS (diluted)$-0.45$-0.33—$-0.44$-0.68$-0.48—$-0.50

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$59M$52M$54M$47M$37M$30M$36M$33M
Inventory————————
Total current assets$116M$133M$122M$132M$148M$155M$178M$208M
Total assets$116M$134M$123M$142M$172M$204M$239M$267M
Long-term debt$12M$17M$22M$27M$30M$30M$29M$30M
Total liabilities$59M$46M$52M$49M$55M$49M$57M$50M
Total equity$57M$87M$70M$93M$117M$156M$182M$217M

Implied volatility — last 90 days

23%205%388%570%752% Jun 17 — IV 532% · EM ±22.2%Jun 19 — IV 60% · EM ±13.3%Jun 22 — IV 60% · EM ±12.5%Jun 29 — IV 138% · EM ±24.4%Jun 30 — IV 141% · EM ±24.3%Jul 08 — IV 175% · EM ±22.0%Jul 09 — IV 188% · EM ±22.2%Jul 13 — IV 431% · EM ±36.0%Jul 20 — IV 86% · EM ±20.4%Jul 22 — IV 435% · EM ±99.5%Aug 03 — IV 272% · EM ±48.2%Aug 04 — IV 267% · EM ±46.1%Aug 05 — IV 180% · EM ±30.1%Aug 06 — IV 237% · EM ±38.4%Aug 07 — IV 138% · EM ±21.5%Aug 10 — IV 155% · EM ±21.5%Aug 14 — IV 119% · EM ±13.1%Aug 19 — IV 752% · EM ±44.4%Aug 24 — IV 39% · EM ±8.1%Aug 25 — IV 24% · EM ±4.8%Aug 26 — IV 25% · EM ±5.0%Aug 27 — IV 25% · EM ±5.0%Aug 28 — IV 27% · EM ±5.1%Aug 31 — IV 30% · EM ±5.3%Sep 01 — IV 30% · EM ±5.1%Sep 02 — IV 29% · EM ±4.8%Sep 03 — IV 30% · EM ±4.9%Sep 04 — IV 30% · EM ±4.7%Sep 07 — IV 34% · EM ±4.7%Sep 08 — IV 359% · EM ±47.5%Sep 09 — IV 350% · EM ±43.9%Sep 16 — IV 97% · EM ±5.7%Sep 17 — IV 140% · EM ±5.8%Sep 23 — IV 236% · EM ±47.2%Sep 24 — IV 263% · EM ±51.5%Sep 25 — IV 152% · EM ±29.0%Oct 02 — IV 314% · EM ±49.0%Oct 05 — IV 354% · EM ±49.0%

Sector peers

CHRS
Coherus Oncology, Inc.
$156M $1.00-1.5%
MOLN
Molecular Partners AG
$143M $3.67-1.3%
HUMA
Humacyte, Inc.
$140M $0.43+5.8%
TARA
Protara Therapeutics, Inc.
$163M $2.34-6.4%
OTLK
Outlook Therapeutics, Inc.
$165M $0.53-5.9%
VYGR
Voyager Therapeutics, Inc.
$165M $1.75-13.4%

ABOS earnings FAQ

What is ABOS's expected move for earnings?

Options currently price a move of about ±49.0%, or $0.98 per share either way from $1.99.

How does ABOS stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.8%, up 0 times and down 2 times.

What is ABOS's implied volatility?

ABOS's at-the-money implied volatility is about 354% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in